Progressing breakthrough RNA therapies with inspired science at ReciBioPharm

Supporting the expanding RNA therapy space at every stage

The number of RNA therapeutics in the development pipeline has increased dramatically in the last five years.* Through continued advancements, RNA therapeutics are becoming more powerful. New therapies are making precise genome and epigenome editing possible for greater control of genes responsible for disease.

However, delivering possible breakthrough RNA-based medicines to clinical trials and beyond in a therapeutic space with relatively new success is no simple task.

Discover how ReciBioPharm is propelling breakthrough RNA therapies.

American Society of Gene+Cell Therapy. Gene, Cell, + RNA Therapy Landscape Report. Q4 2023 Quarterly Data Report.

THE CHALLENGE FACING RNA THERAPY DEVELOPERS

Venturing into a new therapeutic space

We have only begun to realise the potential of RNA therapies. As a result, there are currently no established guidelines for their production, and expertise in the area is limited.

Complex development & manufacturing processes

RNA therapy production is multifaceted. It requires in-depth knowledge of how to develop and manufacture not only nucleic acid but also plasmids and lipid nanoparticles (LNP).

The need for flexibility

The RNA space is rapidly changing. Regulatory bodies are reacting to new advancements and innovation, requiring developers and manufacturers to stay ahead of the curve.

Meeting milestones under tight timelines

RNA developers are under pressure to deliver their innovative therapies rapidly to help patients faster and demonstrate the possibility of a return on investment.

"Other than COVID-19 vaccines — where there were special circumstances — no other RNA therapeutics have successfully reached commercialisation. There are a lot of obstacles to overcome for breakthrough RNA therapies to reach patients."

Melanie Cerullo
Chief Quality & Regulatory Officer, ReciBioPharm

Our solution

As a specialist advanced therapy medicinal product (ATMP) contract development and manufacturing organisation (CDMO) backed by Recipharm's global infrastructure, we offer a range of plasmid, nucleic acid and LNP services, from start to finish. We support the smooth delivery of your RNA projects from pre-clinical to commercial by providing:

All services in one facility

Offering integrated plasmid, nucleic acid, LNP, and fill and finish services, we can help you avoid the complications of multiple tech transfers to streamline timelines.

Our integrated service provides the simplicity of a single team that works closely with you at every step.

Transparent communication

Our teams work together seamlessly to minimise risk and quickly troubleshoot issues that can arise with RNA therapy development and manufacturing processes that inherently overlap.

Through frequent communication and transparency, we quickly overcome challenges when they emerge to ensure RNA projects progress seamlessly.

Flexibility to meet timelines

Being too rigid comes with risk. Supporting your RNA project at every stage from plasmid production to fill and finish, we provide timeline flexibility if problems arise, ensuring each process can be initiated when ready.

Expertise in a space seeing new success

With extensive experience in RNA therapy development and manufacturing, our experts have developed adaptable platforms, helping to meet the unique needs of your RNA project while expediting timelines.

"Flexibility is the key to success for new therapeutic modalities, such as RNA therapies. We can alter our processes to navigate evolving regulatory requirements and meet changing needs as the project progresses."

Jing Zhu,
Vice President, Nucleic Acid & Viral Vector Technology at ReciBioPharm

Rely on us to deliver your next RNA project with certainty

Contact us today